PF-04965842

PF-04965842 Uses, Dosage, Side Effects, Food Interaction and all others data.

PF-04965842 is under investigation in clinical trial NCT03796676 (JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis).

Trade Name	PF-04965842
Availability	Prescription only
Generic	Abrocitinib
Abrocitinib Other Names	Abrocitinib, PF-04965842
Related Drugs	prednisone, Dupixent, Temovate, Lidex, Clobex, Embeline
Type
Formula	C₁₄H₂₁N₅O₂S
Weight	Average: 323.42 Monoisotopic: 323.14159611
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Food Interaction

[Moderate] MONITOR: Smoking during treatment with abrocitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies.

During abrocitinib clinical studies, current or past smokers had an additional increased risk of overall malignancies.

Also, abrocitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.

Administration of abrocitinib with high-fat, high-calorie food increased abrocitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 29% and 26%, respectively, and prolonged the time to reach Cmax by 2 hours.

These changes are not considered clinically relevant.

MANAGEMENT: Caution is advised if abrocitinib is prescribed to current or past smokers.

Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

The manufacturer recommends discontinuing abrocitinib in patients that have experienced a myocardial infarction or stroke.

PF-04965842 may be taken with or without food.